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Abstract 36 
Diet has been investigated in relation to its ability to promote cognitive function. However, evidence 37 
is currently limited and has rarely been systematically reviewed, particularly in a mild cognitive 38 
impairment (MCI) population. This review examined the effect of diet on cognitive outcomes in MCI 39 
patients. A total of five databases were searched to find randomised controlled trial (RCT) studies, 40 
with diet as the main focus, in MCI participants. The primary outcome was incident dementia and/or 41 
Alzheimer’s disease (AD) and secondary outcomes included cognitive function across different 42 
domains using validated neuropsychological tests. Sixteen studies met the inclusion criteria. There 43 
was a high degree of heterogeneity relating to the nature of the dietary intervention and cognitive 44 
outcomes measured, thus making study comparisons difficult. Supplementation with vitamin E (one 45 
study, n 516), Ginkgo biloba (one study, n 482) or Fortasyn Connect (one study, n 311), had no 46 
significant effect on progression from MCI to dementia and/or AD. For cognitive function, the 47 
findings showed some improvements in performance, particularly in memory, with the most 48 
consistent results shown by B vitamins, including folic acid (one study n 266), folic acid alone (one 49 
study, n 180), DHA and EPA (two studies, n 36 and n 86), DHA (one study, n 240) and flavonol 50 
supplementation (one study, n 90). The findings indicate that dietary factors may have a potential 51 
benefit for cognitive function in MCI patients. Further well-designed trials are needed, with 52 
standardised and robust measures of cognition to investigate the influence of diet on cognitive status. 53 
 54 
Background  55 
Cognitive impairment poses a major global public health challenge due to increasing prevalence in 56 
line with population ageing(1). The transition from mild cognitive impairment (MCI) through to the 57 
various forms of dementia, such as Alzheimer’s disease (AD), is one of the costliest burdens on health 58 
service delivery(2). The National Institute for Aging-Alzheimer’s Association (NIA-AA) developed 59 
core clinical criteria to inform the diagnosis of MCI(3). This identifies that a person with MCI should 60 
display a change in cognition, expressed through personal concern or identification from a physician. 61 
Additionally, individuals should display a lower performance in at least one cognitive domain than 62 
that expected for their age and education, over a period of time. Such domains are memory, executive 63 
function, attention, visuospatial skills and language. Finally, individuals with MCI may have slight 64 
problems with complex daily tasks, however, generally live an independent lifestyle with minimal 65 
assistance(3). MCI is described as a transitional stage between the expected cognitive decline of 66 
normal ageing and that of dementia(4). Furthermore, it has been estimated that 46% of MCI patients 67 
develop dementia within three years from diagnosis(5). Therefore, it is critical to identify effective 68 
interventions that can protect against cognitive decline in this vulnerable high risk group (6). 69 
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Despite pharmacological advances, there are no effective treatments to delay or reverse cognitive 70 
impairment. The inflammatory mechanisms and oxidative stress involved in the aetiology of 71 
cognitive decline and dementia(7),  indicates a potential role for nutrition in its prevention(8).  72 
Furthermore, processes such as neurogenesis and neuronal connectivity involved in the function of 73 
the brain are influenced by dietary components(9,10). The role of nutrition in cognitive health outcomes 74 
has been examined in terms of a range of nutrients/dietary patterns, investigating the role that single 75 
nutrients, such as n-3 PUFA(7), as well as whole foods/diet interventions, such as the DASH diet(11), 76 
a ketogenic diet(12), or the Mediterranean diet(13) may have, particularly in relation to their effect on 77 
reducing inflammation and oxidative stress(14,15,16). It has been suggested that, although investigations 78 
into single nutrients have importance from a mechanistic point of view, studies which provide whole-79 
diet analysis acknowledge that, in everyday situations, foods are consumed in complex combinations 80 
and may be a more representative approach to measure the effect of diet on cognition(17). Furthermore, 81 
ensuring older adults with MCI stay physically active could have beneficial effects on cognition(18,19), 82 
alongside engaging in cognitive training strategies to boost cognitive function. This involves a variety 83 
of either computerised or hand-written techniques to enhance memory, language and attention(20). 84 
However, the available research in this area is variable, with a lack of specific studies in MCI(6).  85 
 86 
Ultimately, there is a need for this systematic review to examine what is known to date about the role 87 
of diet on cognitive health, either independently or in conjunction with other lifestyle modifications, 88 
specifically in a MCI population. To our knowledge, the effect of dietary interventions on cognitive 89 
health outcomes, particularly in high risk populations, like MCI has not been previously 90 
systematically reviewed and therefore this has the potential to establish the evidence base for possible 91 
management strategies and also define the scope for future research, if required. Thus, the aim of this 92 
systematic review was to examine the effect of diet, either alone or in combination with lifestyle 93 
and/or cognitive strategies, on cognitive health outcomes in patients with MCI.  94 
 95 
Methods  96 
The methods for this systematic review were based on the Centre for Reviews and Dissemination 97 
(CRD) guidance for undertaking systematic reviews in health care(21). To be included in this review, 98 
the article had to be a randomised controlled trial (RCT) design, conducted in patients with MCI and 99 
with diet as the main focus of the intervention. Pilot studies were excluded when a paper clearly stated 100 
that the research was a “pilot study”. Interventions could focus on diet alone (a dietary pattern or 101 
dietary supplements) or in combination with lifestyle and/or cognitive strategies. An overview of the 102 
inclusion and exclusion criteria is provided in table 1. Incident dementia or AD was the primary 103 
outcome measure. Secondary outcomes included overall cognitive function or specific cognitive 104 
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domains such as memory, executive function, language, attention or visuospatial skills measured 105 
using validated neuropsychological tests for example, Mini Mental State Examination (MMSE), 106 
Cambridge Cognition Examination (CAMcog) or Repeatable Battery for the Assessment of 107 
Neuropsychological Status (RBANS).  108 
 109 
Study Identification 110 
A comprehensive literature search was undertaken in June 2016 using Ovid MEDLINE, EMBASE, 111 
PsycINFO, Web of Science and Scopus. A suitable search strategy was devised considering key terms 112 
used in associated reviews relating to “diet”, “lifestyle”, “cognitive strategies”, “cognition” and 113 
“behaviour change”. Studies were restricted to English Language and similar search terms were used 114 
in each database. This detailed search strategy was developed in Ovid MEDLINE (Supplementary 115 
Material Table 1) and this strategy was tailored for the other databases. The literature search was 116 
repeated in November 2016 and March 2018 to identify new publications. The reference lists of 117 
articles and other relevant systematic reviews were screened for potential trials not identified by the 118 
electronic search.  119 
 120 
Data Extraction   121 
Titles and abstracts of potentially eligible studies were screened by the first author (AMG). Any 122 
articles not meeting the inclusion criteria were excluded at this stage. Full text articles were obtained 123 
for the remaining studies and the study methodology was further assessed for eligibility (AMG). Any 124 
queries with regards to inclusion of articles were discussed among the research team (CME, JW, 125 
BMG and MMK). A data extraction form was generated to summarise the key characteristics of the 126 
included articles, extracting information on participant, intervention, and methodological 127 
characteristics and cognitive outcome results. Data was extracted for the primary and secondary 128 
outcomes as stated previously. Information on quality of life and number of participants experiencing 129 
one or more serious adverse events was also extracted when provided in papers in addition to the 130 
primary and secondary outcomes mentioned. Where studies included validated biomarkers (e.g. 131 
structural MRI or amyloid imaging) secondary to cognitive outcome measures, these data were also 132 
extracted. The extraction was undertaken by the first author (AMG) and this was independently 133 
checked by the second author (CME) and both reviewers discussed any discrepancies as required.  134 
 135 
Quality Assessment  136 
The methodological quality of the included studies was assessed using the JADAD scale(22). This 137 
scale has been widely used to assess the quality of RCTs included in systematic reviews with regards 138 
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to randomisation procedures, double blinding and participant withdrawals. A score of 1 was allocated 139 
for each “yes” answer to the following three questions;  140 
(1) Was the study described as randomised? 141 
(2) Was the study described as double blind?  142 
(3) Was there a description of withdrawals and drop outs?  143 
An additional score of 1 was awarded if;  144 
(4) The randomisation process was described and appropriate 145 
(5) The method of double blinding was described and appropriate.  146 
The maximum possible score was 5(22). 147 
The risk of bias was assessed using the Cochrane classification(23). Each study was assessed for the 148 
following (where appropriate): (1) selection bias; (2) performance bias; (3) detection bias; (4) attrition 149 
bias and (5) reporting bias. Individual studies were assessed as either low, high or uncertain risk for 150 
the adequacy of the stated variables.  151 
 152 
Data Analysis 153 
The data collected were expected to display a high degree of heterogeneity, therefore quantitative 154 
synthesis was unsuitable. The results were summarised using narrative synthesis and presented in 155 
tables. 156 
 157 
Results 158 
The systematic search in June 2016 generated a total of 2130 articles (2108 through database searches 159 
and 22 through searches of reference lists). Following the removal of 650 duplicates, 1480 articles 160 
were screened for eligibility by examining their titles and abstracts. This process excluded 1447 161 
studies and the full texts of 33 papers were obtained; 22 articles were excluded for the reasons outlined 162 
in figure 1. Following a 2nd (November 2016) and 3rd (March 2018) literature search, five further 163 
studies were identified that met the inclusion criteria and so 16 studies were included. As per the 164 
review protocol, the results have been displayed according to the primary (incident dementia or AD) 165 
and secondary (cognitive function) outcomes. For cognitive function, as per the NIA-AA criteria for 166 
the diagnosis of MCI(3), the results were grouped according to the following cognitive domains: (1) 167 
memory; (2) executive function; (3) attention; (4) language and (5) visuospatial skills, with an 168 
additional section reporting global cognitive function. When papers did not specify the cognitive 169 
domain measured, the results were grouped under “additional cognitive function measures” 170 
(supplementary material, table 2). A descriptive list of the most frequently reported cognitive function 171 
tests used in the studies is provided in the supplementary material.  172 
 173 
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Study Characteristics  174 
An overview of the study characteristics is shown in table 2. Of the 16 studies included in analysis, 175 
13 studies used dietary supplements or single foods as their diet intervention, including folic acid(24), 176 
Vitamin B combination (folic acid, vitamin B12 and vitamin B6)(25), Gingko Biloba(26), n-3 fatty acids 177 
(DHA+EPA(27,28,29) and DHA(30)), Vitamin E(31), Chromium supplementation(32), the medical food, 178 
Souvenaid containing the specific nutrition combination Fortasyn Connect(33), cocoa flavanols(34), 179 
Concord grape juice(35) and wild blueberry juice(36). The three remaining studies focused their 180 
interventions on nutritional counselling in combination with healthy eating advice and calorie 181 
restriction(37), high–saturated fat/high–glycaemic index diet vs a low–saturated fat/low–glycaemic 182 
index diet(38) and a high carbohydrate vs a very low carbohydrate diet(12). A figure detailing the 183 
included studies and their dietary exposure linked to the cognitive outcome measures assessed is 184 
provided in the supplementary material (Figure 1). One study(37) encouraged both intervention and 185 
control participants to partake in physical activity (150 minutes per week) as per World Health 186 
Organisation (WHO) recommendations(39). There were no studies which included cognitive strategies 187 
as part of their intervention. Furthermore, two studies stated that participants had amnesic MCI 188 
(aMCI)(38) or prodromal AD(33) while all other studies reported a diagnosis of MCI.  189 
 190 
Primary Outcome Measure – Incident Dementia and Alzheimer’s disease 191 
Three of the included studies had an outcome measure of incident dementia and/or AD(26,31,33). 192 
Vitamin E supplementation over three years showed no significant difference in the diagnostic rate 193 
of AD in participants with MCI taking vitamin E (2000 IU) vs placebo (Hazard ratio (HR) 1.02, 95% 194 
CI 0.57-1.13)(31). In the vitamin E group, 33/257 (13%) and 38/259 (15%) participants in the placebo 195 
group progressed to possible or probable AD in the first 12 months (RR 1.02, 95% CI 0.96-1.10). At 196 
36 months, 76/257 (30%) in the vitamin E group and 73/259 (28%) in the placebo had progressed to 197 
AD (RR 1.03, 95% CI 0.79-1.35)(31). Likewise, a USA based study with intervention follow up over 198 
6.1 years and found no significant difference between Gingko Biloba vs placebo for the outcomes of 199 
all dementia (9.82/100 person-years vs 8.68/100 person-years, HR 1.13, 95% CI 0.85-1.50), AD 200 
without vascular dementia (VaD) (7.02/100 person-years vs 6.09/100 person-years, HR 1.15, 95% CI 201 
0.83-1.61), AD with VaD (2.10/100 person-years vs 2.20/100 person years, HR 0.96, 95% CI 0.54-202 
1.71), total AD (9.12/100 person-years vs 8.28/100 person-years, HR 1.10, 95% CI 0.83-1.47) and 203 
VaD without AD (0.18/100 person-years vs 0.30/100 person-years, HR 0.59, 95% CI 0.10-3.51)(26). 204 
Finally, supplementation with Souvenaid (125ml/day of the specific nutrition combination Fortasyn 205 
Connect) vs control, showed no statistically significant difference in diagnosis of dementia at 24 206 
months between groups (59/158 (37%) (control) vs 62/153 (41%) (intervention))(33). 207 
 208 
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Secondary Outcome Measure- Cognitive Function 209 
Memory 210 
As shown in table 3, there were 25 cognitive tests used to measure the domain of memory, and it was 211 
assessed in 15 out of the 16 studies (94%) and hence was the most tested cognitive domain. Overall, 212 
nine out of the 15 studies (53%) (B vitamin(25), DHA+EPA(27,28,29), DHA(30), vitamin E (31), cocoa 213 
flavonols(34), concord grape juice(35) and wild blueberry juice(36)) showed a significant difference 214 
between groups at study completion in at least one cognitive function test measuring memory. Fish 215 
oil supplementation (3x 430 mg DHA + 150 mg EPA daily for 12 months), produced significant 216 
improvements in visual reproduction I and RAVLT delayed recall vs placebo group (all p<0.05) (27). 217 
In addition, there was a significant improvement in memory performance (cognitive Z score) in the 218 
fish oil vs placebo group (p= 0.001)(27). In a second study investigating n-3 polyunsaturated fatty acid 219 
supplementation (480mg DHA + 720mg EPA daily for 6 months vs  placebo)(28), borderline statistical 220 
significance (p=0.047) was reported between intervention and control for working memory. 221 
However, a third study investigating 625mg EPA+600mg DHA vs placebo showed no significant 222 
improvements in memory(29). A fourth study who investigated DHA supplementation only (2mg/day 223 
vs placebo)(30), found significant improvements for short-term memory (p = <0.0001) and long-term 224 
memory (p = <0.0001) in comparison to the placebo group. In a trial investigating the effect of cocoa 225 
flavanols (High Flavonols (HF) 990 mg vs Intermediate Flavonols (IF) 520 mg vs Low Flavonols 226 
(LF) 45 mg of flavanols daily for 8 weeks)(34), verbal fluency test scores significantly improved (p = 227 
0.0001), with a significantly greater score in HF participants in comparison with the LF group (p = 228 
<0.05).  229 
 230 
B vitamin supplementation(25) (0.8mg folic acid, 0.5mg vitamin B12, 20mg vitamin B6 daily for 2 231 
years), demonstrated improvement in verbal memory but only in those participants with low baseline 232 
B vitamin/folic acid status. The odds of correctly remembering a word in the HVLT test were 69% 233 
greater for a person in the high tHcy group if they were taking B vitamins, than if they were taking 234 
placebo (OR =1.69, p=0.001)(25). For category fluency (CERAD), in the high tHcy group, the average 235 
number of words was 9.4% greater at follow up in those on B vitamin treatment compared with the 236 
placebo (p= 0.04). However, in the low tHcy group (indicating higher B vitamin/folic acid status) 237 
there was no significant difference between the treatment group and placebo(25). In another B vitamin 238 
study, investigating folic acid alone (400 μg daily for 6 months) vs conventional treatment(24) results 239 
showed for short term memory that the intervention group had a significant increase in score from 240 
baseline to 6 months in comparison to the control (p = <0.001). Results also indicated that elevated 241 
homocysteine levels at baseline were associated with significantly poorer cognitive performance at 242 
intervention completion for the intervention group in comparison to the control(24).  243 
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Vitamin E supplementation (2000IU daily for 2 years)(31), the medical food, Souvenaid containing 244 
the specific nutrition combination Fortasyn Connect (125ml daily)(33) and Chromium picolinate 245 
(CrPic) supplementation (1000 mcg daily for 12 weeks)(32) had no significant improvement in 246 
comparison to placebo for memory. Supplementation with CrPic showed significantly reduced 247 
intrusion errors, with the intervention group making significantly fewer errors on CVLT for learning 248 
(p = 0.01)  than the placebo group, however there was no significant reduction for recall and 249 
recognition memory(32). In an investigation of the effects of a high carbohydrate diet (50% of total 250 
calories) vs a very low carbohydrate (5-10% of total calories) diet in participants with MCI(12), pre-251 
intervention carbohydrate levels were recorded as 207g for those in the “high” carbohydrate group 252 
and 190g in the “low” carbohydrate group. Post-intervention carbohydrate levels measured 197g for 253 
the “high” carbohydrate group and 34g for the “low” carbohydrate group. These figures indicate that 254 
those in the “low” group had a major dietary change whereas the “high” group could be regarded as 255 
a control. Results showed no significant effect of the intervention for memory performance (brief 256 
visuospatial memory test, story recall and word list) between intervention and control groups(12). 257 
Concord grape juice(35) (daily consumption between 6-9ml/kg for 12 weeks) significantly improved 258 
verbal learning compared to the placebo (p = 0.04). However, there were no significant differences 259 
between those consuming the grape juice and placebo for delayed verbal recall and spatial memory(35). 260 
Furthermore, wild blueberry juice(36) (daily consumption between 6-9 mL/kg for 12 weeks) had a 261 
significant improvement from baseline score to 12 weeks for V-PAL cumulative learning (p= 0.009). 262 
In addition, mean scores for CVLT word list recall improved significantly within the intervention 263 
group from baseline to 12 weeks (p = 0.04). There was a significant difference in V-PAL score 264 
between intervention and control groups (p = 0.03), however no significant difference was observed 265 
for CVLT performance between groups(36).  266 
 267 
Executive Function 268 
The domain of executive function was measured by 12 tests (table 3). For this cognitive domain, 269 
measured within nine studies (56%), two RCTs showed a statistically significant improvement 270 
between groups at study completion(25,34). At 24 months follow-up, the odds of a correctly drawn item 271 
from CLOX1, after controlling for confounders (CLOX2 at follow-up, CLOX1 at baseline, age, 272 
education, APOE Ɛ4 status and sex), was 30% greater in those receiving B-vitamins vs placebo (p = 273 
0.02)(25). For cocoa flavonol supplementation(34), better scores for trail making test, part B (p = <0.05) 274 
were reported among participants who received HF and IF treatments vs the LF group. In addition, 275 
the time required to complete the trail making task, B significantly changed during the duration of 276 
the study (p = <0.0001). However, DHA+EPA supplementation(27,29), nutritional counselling with 277 
calorie restriction(37), high fat/high GI vs low fat/low GI diet(38), high carbohydrate vs low 278 
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carbohydrate diet(12), supplementation with Fortasyn Connect (Souvenaid)(33) and vitamin E(31) 279 
showed no significant difference in cognitive function tests between groups at study completion. 280 
There was a significant improvement in comparison with placebo at six months for those consuming 281 
vitamin E supplements (p<0.05)(31). However, thereafter, this significant difference was not 282 
maintained beyond this time point.  283 
 284 
Attention  285 
As shown in table 3, five of the 16 (31%) included studies measured the domain of attention. 286 
Nutritional counselling vs standard care showed no significant change in attention between groups 287 
after 12 months(37). Whereas, cocoa flavonol supplementation(34), significantly better scores for trail 288 
making test, part A (p = <0.05) were reported among participants who received HF and IF treatments 289 
in comparison to the LF group. In addition, the time required to complete the trail making task, part 290 
A significantly changed during the duration of the study (p=<0.0001)(34). DHA+EPA 291 
supplementation(27) (one study) showed a significant improvement in digit span score from baseline 292 
to 12 months in the fish oil group vs placebo (p = <0.0001)(27). However, there was no significant 293 
treatment effect reported between the fish oil and placebo groups for any of the other measures of 294 
attention(27). Supplementation with DHA only(30) showed significant improvements in digit span score 295 
in comparison to the placebo (p=<0.0001). However, a third study with DHA+EPA 296 
supplementation(29) found no significant differences between groups for attention.  297 
 298 
Language 299 
Two of the 16 (13%) studies measured the cognitive domain of language (table 3). There were no 300 
significant differences between groups for nutritional counselling with calorie restriction(37). For 301 
vitamin E supplementation(31), there was a significant difference in score from the baseline value 302 
between groups at 6 months (p = <0.05), 12 months (p = <0.05) and 18 months (p = <0.05), however, 303 
thereafter this significant difference was not maintained until intervention completion (36 months)(31).  304 
 305 
Visuospatial skills  306 
Four studies (25%) measured the cognitive domain of visuospatial skills (table 3). Supplementation 307 
with folic acid was the only study to show a significant interaction effect between groups for 308 
visuospatial skills (p =0.03)(24). In addition, higher baseline homocysteine levels were associated with 309 
poorer cognitive performance on the block design test at the end of the intervention in comparison 310 
with the placebo (estimate value = −0.079, p = <0.001)(24). Fish oil supplementation with concentrated 311 
DHA+EPA(27) , DHA(30) or vitamin E supplementation(31) did not show any significant differences 312 
between groups.  313 
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Global Cognitive Function 314 
For cocoa flavonol supplementation(34) (supplementary material table 2), there was no significant 315 
change in MMSE score between the HF, IF or LF treatment groups over the duration of the study (p 316 
= 0.13). However, results also showed that the composite cognitive Z score significantly changed 317 
during the study (p=<0.0001). The cognitive Z score at the end of the study follow-up was 318 
significantly (p=<0.05) better in the HF group in comparison to the LF group(34). Vitamin B 319 
supplementation(25) indicated no significant effect of treatment (p=0.57) on global cognition as 320 
measured by MMSE. However, analysis did show that those who had high baseline concentrations 321 
of homocysteine and were treated with B vitamins, were 1.58 more likely to provide a correct answer 322 
on the MMSE test than the placebo group (p <0.001). However, there was no significant difference 323 
for those with low baseline homocysteine, between the B vitamin or placebo groups. Similarly, fish 324 
oil supplementation(27) (one study) showed no statistically significant differences between groups for 325 
cognitive function as measured by the MMSE.  Furthermore, vitamin E supplementation(31) at 6 326 
months intervention showed a significant difference in comparison with placebo for overall cognitive 327 
function calculated by a composite Z score (p=<0.01). However, at 36 months this significant 328 
difference between groups was not maintained.  329 
 330 
Assessment of Methodological Quality and Risk of Bias 331 
The quality(22) of the 16 included studies varied, with eight studies achieving the maximum total score 332 
of 5(25-28,30,31,33,34) (supplementary material table 3). Thus, it was deemed that these studies stated 333 
appropriate randomisation processes, were clearly indicated as double blinded and the authors 334 
accounted for any participant withdrawals during the study. Two studies(12,38) scored one on the Jadad 335 
scale(22) and stated that participants were randomised however did not specify the randomisation 336 
process, if double-blinding took place and if any participant withdrawals occurred. Low risk of bias 337 
scores(23) were allocated for selection bias (n=9)(24-28,30,31,33,34), performance bias 338 
(n=7)(25,26,28,29,30,33,34), attrition (n=9)(24,25,27-30,33,34,37) and detection bias (n=6)(24,26,30,33,34,37) 339 
(supplementary material table 4).  A high risk score was documented for detection bias (n=3)(12,38) 340 
and performance bias (n=2)(12) as there were no details provided of any double blinding method used.  341 
 342 
Discussion 343 
The aim of this systematic review was to examine the effect of diet, either alone or in combination 344 
with lifestyle and/or cognitive strategies, on cognitive health outcomes in patients with MCI. Together 345 
with the limited number of RCTs conducted and the heterogeneity of the studies in this review, a 346 
narrative synthesis of the findings was implemented. Studies varied greatly in terms of the nature of 347 
dietary intervention and cognitive outcome measures used. Furthermore, there were no studies that 348 
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measured the effectiveness of lifestyle and/or cognitive strategies in combination with their dietary 349 
intervention. Overall, it was evident that the findings were inconsistent across the studies and do not 350 
provide clear evidence to support the effect of any specific diet or dietary component on cognition in 351 
MCI patients. 352 
 353 
Diet has been suggested to have a significant association with cognitive decline and progression to 354 
dementia, particularly showing a protective role against the harmful effects of neuro-inflammation 355 
and oxidative stress(40). Although the pathways related to their role are complex and variable 356 
throughout the literature(14,15,16,41) it is thought that antioxidants in foods such as fruit and vegetables 357 
help to reduce oxidative stress levels in the brain and n-3 PUFAs in foods such as oily fish, are 358 
additionally linked to reduced inflammation(8). There are plausible suggestions to support these 359 
mechanisms by the results of this review. There were some improvements in cognitive function, 360 
particularly in the domain of memory, reported for polyphenol compounds (e.g. cocoa flavonols(34)), 361 
fish oil supplementation with concentrated DHA+EPA(27,28) or DHA alone(30) and beverages which 362 
are high in these bioactive, antioxidant properties e.g. Cocord grape juice(35) and wild blueberry 363 
juice(36). However, some of these studies either had small, potentially underpowered sample sizes, 364 
used a limited number of cognitive tests to measure outcomes or had shorter intervention durations 365 
therefore these results should be interpreted with caution.  366 
 367 
Nutrient and Food Supplementation 368 
As mentioned, antioxidant compounds such as vitamins A, C and E have a role in regulation of 369 
oxidative stress, a pathway linked with neurodegeneration and cognitive decline(42). However in this 370 
review, diet supplementation with vitamin E(31) had no significant effect on progression from MCI to 371 
dementia and/or AD or on cognitive function at intervention completion. Furthermore, meta-analyses 372 
have reported no significant effect of vitamin E on cognitive function outcomes(43,44). The particular 373 
form of vitamin E used could have an influence on the impact of this nutritional component on 374 
cognitive decline, with research suggesting total tocopherol plasma concentrations rather than single 375 
tocopherols may be more valuable at predicting cognitive impairment, particularly AD(45). 376 
Furthermore, as we consume foods in complex patterns, resulting in ingestion of combinations of 377 
various forms of vitamin E, it may be more beneficial to focus research efforts away from single 378 
forms and follow a more holistic investigation(15). In this review, supplementation with cocoa 379 
flavonols(34) showed better cognitive performances for those who received higher flavonols 380 
concentrations compared to lower concentrations. There are suggestions in the literature that 381 
flavonoids may exert their neuroprotective properties in a similar mechanism to antioxidants in the 382 
body(46). However, further indications suggest that flavonoids may have a more prominent role in the 383 
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regulation of neuronal signalling pathways(47) or neuro-inflammation(48). It is clear that further 384 
research is required to fully explore the mechanism of action of flavonoid compounds and investigate 385 
the potential role they may have in protecting against cognitive decline(49).  386 
 387 
Low folate and B vitamin status is linked to cognitive dysfunction during the ageing process and 388 
better cognitive performances have been associated with higher intakes of B vitamins(50,51,52). 389 
Furthermore, increased levels of homocysteine have been linked to poorer cognition, particularly in 390 
memory and attention(53,54,55). This may be explained by the role that B vitamins have in one-carbon 391 
metabolic pathways in the body, acting as co-factors for the remethylation of homocysteine to 392 
methionine, producing the methyl-donor, S-adenosylmethionine. This methyl donor has a specific 393 
role in the methylation of phospholipids and neurotransmitters in the brain, thus indicating how a 394 
depletion in B vitamins status may influence cognitive function and ultimately, cognitive 395 
impairment(56,57).  In this review, supplementation with a B vitamin combination(25) or with folic acid 396 
alone(24) had significant effects on executive function(25) and furthermore, when baseline 397 
homocysteine levels were elevated, there were significant improvements in global cognition(25), 398 
memory(24,25) and visuospatial skills(24). In support, not only have improvements been observed in 399 
performance based cognitive tests, B vitamin supplementation (folic acid, vitamin B6 and B12 400 
combination) have resulted in reduced rates of brain atrophy in MCI(58,59); a process which could 401 
result in progression to AD if allowed to advance. However, findings are mixed with meta-analyses 402 
of clinical trial data reporting no significant effect of B vitamins on cognitive function(43,60). 403 
Therefore, further trial research is warranted to confirm the role of B vitamins in reducing cognitive 404 
decline.  405 
 406 
Polyunsaturated fatty acids have been associated with promoting cognitive function, primarily as a 407 
result of their anti-inflammatory properties(61). Furthermore, n-3 fatty acids, particularly DHA, are a 408 
key component of neuronal membranes in the brain, influencing neurogenesis and neuronal 409 
function(41,62). In this review, supplementation with DHA+EPA(27,28) reported significant 410 
improvements in the domain of memory, with DHA supplementation alone(30) showing an additional 411 
improvement in attention, albeit by a single cognitive test. In contrast, evidence from meta-analyses 412 
have reported no significant effect of omega 3 fatty acids on cognitive outcomes(43,62). Furthermore, 413 
it has been suggested that fatty acid supplementation in individuals who are homozygous carriers of 414 
the APOE Ɛ4 allele, a risk factor for cognitive decline, could be resistant from the potential protective 415 
effects of fatty acids on cognitive health(63). Thus, this is an important covariate to consider when 416 
designing trials to test effectiveness of fatty acid supplementation. However, some observational 417 
evidence does exist to support the role of n-3 fatty acids in promoting cognition with a study that 418 
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followed non-demented participants for 4 years, finding higher plasma EPA concentrations to be 419 
associated with a lower incidence of dementia(64). In addition, an intervention study with older adults 420 
with subjective memory impairment investigated fatty acid supplementation (EPA+DHA) vs corn oil 421 
placebo(65). Results showed significantly improved cortical blood oxygen level-dependent (BOLD) 422 
activity during a working memory task in the fish oil group compared to placebo. In this review, one 423 
study investigating DHA+EPA supplementation(29) found no effect on cognitive function in 424 
comparison to control. A plausible explanation for this finding could be that the placebo used this 425 
study was olive oil, a component of the Mediterranean Diet associated with improved cognitive 426 
function owing to its anti-inflammatory properties(66). Therefore, further investigation of the role of 427 
fatty acids and cognitive decline is justified through well-designed, robust studies. 428 
 429 
Whole-foods/dietary patterns 430 
Only three of the 16 studies included in this review(12,37,38), focused their diet intervention on “whole-431 
foods/dietary patterns” rather than single-nutrient supplements or single food products. In everyday 432 
situations, individuals consume holistic dietary patterns which involve complex interactions between 433 
nutrients(67). It therefore could be suggested that the more representative intervention design to 434 
measure the effects of diet on cognition could be that which involved a dietary pattern rather than 435 
focused on a single nutrient. In this review however, these studies were heterogeneous in terms of the 436 
dietary intervention and reported mixed findings. Research evidence suggests that ketogenic diets(68) 437 
and calorie restriction(69) may have a promising, yet under-investigated, role in AD prevention, 438 
suggesting links to brain glucose metabolism(68), reduction in oxidative stress(69), and anti-439 
inflammatory mechanisms(69). There is also emerging evidence from observational studies to suggest 440 
a protective role for healthy dietary patterns such as the Mediterranean Diet (MD) on MRI measured 441 
brain structures(70,71,72) and therefore further investigation of such dietary patterns is necessary, with 442 
the inclusion of more rigorous assessment measures, to help to provide insight into potential 443 
mechanisms of how diet can impact brain health.  444 
 445 
Use of Biomarkers and Cognitive Markers  446 
CSF biomarkers may be a valuable asset in detecting pathological changes in neurological diseases, 447 
owing to the processes of extracellular amyloid-β deposition and accumulation of 448 
hyperphosphorylated tau proteins(73). One study(38) in this review included biomarker analysis in 449 
addition to cognitive test measures. Increased concentrations of CSF Aβ42 were observed in those 450 
with aMCI consuming a low diet (low saturated fat/low GI) in comparison to healthy controls who 451 
observed a decrease in CSF Aβ42 levels (supplementary material). Thus, CSF biomarkers in this 452 
study changed in response to diet in aMCI patients in the absence of any discernible changes in 453 
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cognitive function test scores, albeit in very small sample. These differences could provide insights 454 
into the mechanisms of action of beta-amyloid in the body in cognitive impairment. In particular, 455 
biomarker analysis may be more sensitive to dietary changes and could be an important consideration 456 
for future dietary intervention studies as the use of biomarkers could be a more rigorous approach to 457 
assess cognitive performance in this patient group(74). Furthermore, it has been suggested that the use 458 
of brain imaging as a cognitive marker such as MRI scanning is a more robust measure of cognition 459 
in comparison to questionnaire based tests(50,75). Three studies in this review reported on cognitive 460 
marker information, including MRI(30,33) and fMRI imaging(32), as an additional outcome measure for 461 
cognitive function, depicting some significant interaction effects for the intervention group that were 462 
not entirely reflected by cognitive function tests (supplementary material). Brain imaging techniques 463 
have been used in nutrition and cognition research, with investigations into B vitamins utilising MRI 464 
scanning to detect changes in brain atrophy in MCI(58,59), fMRI scanning to explore fish oil 465 
supplementation in older adults with subjective memory impairment(65) as well as investigations of 466 
beta-amyloid load using positron emission tomography (PET) and neuronal activity via PET imaging 467 
with 2-[18F]fluoro-2-Deoxy-D-glucose (FDG)(76). Therefore, the use of these higher quality methods 468 
could be implemented in future dietary intervention trials to comprehensively measure the potential 469 
effects of diet on cognition and explore mechanisms. 470 
 471 
The mixed evidence found on the effect of diet on cognition among MCI participants may be 472 
explained by the heterogeneity of studies included, owing to variation in cognitive outcome measures 473 
used, differences in the diet intervention type (supplements vs single food products vs dietary 474 
patterns), variations in sample size and duration of intervention. Furthermore, the small number of 475 
dietary intervention studies conducted among this patient group make it difficult to provide 476 
conclusive evidence to support the effect of diet on cognitive outcomes. Of the 16 included studies, 477 
those with B vitamin and/or folic acid supplementation(24,25), DHA/EPA supplementation(27,28,30) or 478 
cocoa flavonol rich drinks(34) appeared to have the most consistent effects on cognitive outcomes. 479 
However, it is difficult to confirm that these dietary interventions are the most effective in terms of 480 
promoting cognitive function due to the low number of studies testing the same intervention. 481 
Nonetheless, the outcomes of the systematic review highlight the need for well-designed, robust 482 
RCTs, with pretested and informed methodological characteristics to further explore the role of diet 483 
in cognitive decline.  484 
 485 
Limitations  486 
During the literature search for this review, a broad search strategy was used to ensure the search 487 
covered all related aspects to the reviews aims and objectives. However, search limitations were set 488 
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to only include studies in English language and the grey literature was not included for this review, 489 
therefore this could have resulted in language and publication bias. As RCTs were the study design 490 
of choice for inclusion, this may have caused selection bias. However, as RCTs are considered the 491 
best design for assessing the effect of a dietary intervention with their ability to identify causality(77), 492 
this therefore provides justification for the decision. Pilot studies were not included in this review, as 493 
these studies are likely to have an underpowered sample size. The number of studies included in this 494 
review were small, however, as there are few RCTs completed in this area, this supports the need for 495 
further intervention studies to increase the evidence-base. Due to the heterogeneity of the included 496 
studies, the data was not meta-analysed. Instead, a rigorous narrative review was implemented. Study 497 
characteristics, such as short study durations, may have not provided sufficient time to view a change 498 
in cognitive outcomes. It has been suggested that long term, RCTs are the best approach in the design 499 
of a nutritional intervention to measure cognitive performance, with estimations that the most effect 500 
preventative trials require up to 3-5 years duration and follow-up(78). Furthermore, ensuring a 501 
sufficient sample size though determination by a power calculation will provide a more stringent 502 
approach to the research design. Therefore, it is important when designing intervention studies that 503 
duration and sample size are pre-tested, though a feasibility study or by comparison to similar studies 504 
in the field. 505 
 506 
Eight of the 16 studies in this review achieved the maximum quality score as assessed by the Jadad 507 
scale(22). Those studies who received the lowest scores failed to provide details on the randomisation 508 
and blinding processes which took place in the study. It is important to note however, as both studies 509 
involved a dietary pattern intervention rather than a supplement/placebo, it is impractical to ensure 510 
participants and researchers are blinded to the intervention group. Therefore, the decision that these 511 
studies are of “low quality” is difficult to confirm.  Furthermore, for risk of bias, a number of studies 512 
were allocated uncertain risk for selection, performance, attrition and detection bias due to inadequate 513 
information on randomisation, double blinding and/or withdrawals. Finally, a challenge within this 514 
review was the heterogeneity of cognitive outcome measures used to determine cognitive change. 515 
Some studies grouped results by domain, while others by the single cognitive tests used. This made 516 
it difficult when presenting the results of this review, as some study results did not exactly fit within 517 
the cognitive domains, as these were not specified in the original paper. In line with the NIA-AA 518 
criteria for the diagnosis of MCI(3), which state that for a diagnosis of MCI individuals must have 519 
deterioration in one or more cognitive domains, it would be beneficial for analysis purposes if future 520 
intervention studies could assess cognition based on these domains to allow better comparison of 521 
results. However, in saying that, even the tests used to measure cognition within domains vary greatly 522 
and there is a lack of standardisation. It is evident therefore, that there is a demand to determine a 523 
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specialised cognitive test battery that can be used to measure change in cognition, particularly within 524 
an MCI population. Furthermore, change in cognition requires time, more rigorous examinations and 525 
evaluation by clinical specialist(79). These are all important considerations for future intervention trials 526 
going forward. 527 
 528 
Conclusion 529 
To date there is insufficient RCT evidence on the effect of whole diets or specific dietary components 530 
on cognitive outcomes in MCI patients. Existing studies are heterogeneous in terms of the dietary 531 
intervention, duration, sample size and cognitive outcome measures assessed, with the most 532 
consistent results for cognitive function shown by B vitamins, folic acid, DHA and/or EPA and cocoa 533 
flavonol supplementation. Further exploration of the potential beneficial effect of diet on cognitive 534 
outcomes in MCI is merited. 535 
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Table 1: An overview of the inclusion and exclusion criteria for this systematic review 
 Inclusion Criteria  Exclusion Criteria  
Study design  Randomised controlled trial (RCT)  Observational study design; Pilot studies, when a 
paper clearly stated that the research was a “pilot 
study” 
 
Intervention Dietary Intervention either diet alone (a 
dietary pattern or dietary supplements) or 
in combination with lifestyle and/or 
cognitive strategies 
 
Medical type intervention in conjunction with 
either a diet/lifestyle/cognitive intervention with 
undifferentiated results 
Control Control interventions that were not 
expected to have specific risk-modifying 
effects; Control arms would typically 
involve no intervention, usual diet or 
placebo. 
 
Studies with no comparator, placebo or control 
Diagnosis of 
MCI 
Diagnosis of MCI was necessary by a 
medical physician or according to 
internationally accepted and validated 
classifications or criteria 
“Memory problems” or “self-reported memory 
complaints” and no clear diagnosis of MCI; A 
diagnosis of dementia or any other form of 
cognitive impairment other than MCI, unless 
results for MCI participants were presented 
separately; “Cognitively healthy adults” 
 
Participants 
 
Community dwelling participants; No 
restrictions made based on gender or age 
  
Individuals who were hospitalised, in a 
rehabilitation or long-term care facility; 
Participants with psychiatric problems e.g. 
depression or any significant medical 
comorbidity, or history of, a comorbid condition 
that may alter performance on cognitive tests, e.g. 
stroke, head injury, Parkinson’s disease, learning 
disability 
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Table 2: Overview of study characteristics 
Author, Year 
and Location 
MCI sample 
characteristics  
Diagnostic 
Criteria for MCI 
Intervention Study 
Duration 
Outcome Measures 
Bayer-Carter et 
al., 2011(38) 
(n=49) 
 
USA 
68.4 years  
 
aMCI = 29 
  High = 15 
  Low =  14 
Healthy Controls = 20 
  High = 9 
  Low = 11 
Lost to follow up = no 
detail 
Petersen (2004)(82) Intervention groups:  
(1) High diet- 45% fat (saturated fat 25%), 35-
40% carbohydrate (glycaemic index >70) and 
15-20% protein.  
(2) Low diet- 25% fat (saturated fat <7%), 55-
60% carbohydrate (GI <55) and 15-20% protein. 
Control group: Healthy adult control group.  
 
4 weeks Immediate and delayed memory: 
Story recall, word list, brief 
visuospatial memory test; Executive 
Function: Trail making test part B, 
Stroop test, Verbal fluency test; 
Motor speed: Trail making test part 
A, Stroop test; AD biomarkers  
CSF Aβ42, CSF Aβ40, tau protein 
phosphorylated tau (p-tau), 
Apolipoprotein E (APOE) 
 
Horie et al., 2016 
(n=80)(37) 
 
Brazil 
68.1 years  
 
Intervention = 40 
Control = 40 
Lost to follow up = 5 
European 
Consortium on 
Alzheimer’s 
Disease (80) 
Intervention group: caloric restriction and 
counselling with nutritionists (26-28 x1 hour 
meetings). Advice- eating a diet rich in fibre, 
fruits, vegetables, wholegrains and included at 
least 1g/kg body weight of protein per day. 
Recommended calorie deficit of approx. 500 
kcal/day (min 1200kcal per day).  
Control group: conventional medical care with 
consultant Geriatrician.  
 
All participants were advised to engage in 
physical activity (at least 150 minutes per week 
of moderate intensity aerobic activity or 
walking)(35)  
 
12 
months 
Verbal Memory: RAVLT delayed 
recall, total learning and recall 
recognition; Attention: Digit span 
forward, Digit span backward, Trail 
making test part A; Working 
Memory: Digit span backwards, Trail 
making test part; Psychomotor 
processing speed: Trail making test 
part A, Trail making test part B; 
Executive Function: Modified 
Wisconsin Card Sorting Test, Trail 
making test part B, verbal fluency; 
Language: Phonemic verbal fluency, 
Semantic verbal fluency  
 
Krikorian et al., 
2012 (12) 
(n=23) 
 
USA 
70.1 years 
 
High Carbohydrate = 11 
Low Carbohydrate = 12 
Lost to follow up =0 
Clinical Dementia 
Rating (CDR) (81) 
Intervention groups: High carbohydrate (50% 
of total calories) vs a very low carbohydrate 
group (5-10% total calories). Intake of protein 
and fat were allowed to vary and total calorie 
intake was not restricted 
 
 
6 weeks Working memory and executive 
ability: Trail making test, part B 
Secondary or long term memory: 
Verbal paired associate learning test 
(V-PAL) 
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Table 2: Overview of study characteristics 
Author, Year 
and Location 
MCI sample 
characteristics  
Diagnostic 
Criteria for MCI 
Intervention Study 
Duration 
Outcome Measures 
de Jager et al., 
2012(25) 
(n= 266) 
 
UK 
76.8 years  
 
Intervention = 133 
Control = 133 
Lost to follow up = 43 
Petersen Criteria 
(2004)(82) 
   
Intervention group: 0.8mg folic acid, 0.5mg 
vitamin B12, 20mg vitamin B6 (daily).   
Control group: vitamin-free tablets of similar 
appearance.  
2 years Global cognition: MMSE; Episodic 
Memory: HVLT-R; Semantic 
Memory: Category fluency CERAD; 
Executive Function: CLOX; Clinical 
outcome measures: CDR 
 
Ma et al.,  
2016(24) 
(n=180) 
 
China 
65 years  
 
Intervention = 90 
Control = 90 
Lost to follow up = 21 
Petersen Criteria 
(2004)(82) 
Intervention group: oral folic acid (400 μg/day). 
Participants were instructed to supplement with 
one tablet daily, during, or immediately after a 
meal. 
Control group: Conventional medical treatment 
6 Months Chinese version of the WAIS-RC- 
Information, Similarities, Vocabulary, 
Comprehension, Arithmetic, Digit 
Span, Block Design, Picture 
Completion, Digit Symbol-Coding, 
Object Assembly & Picture 
Arrangement 
 
DeKosky et al., 
2008(26) 
(total study n= 
3069, n=482 with 
MCI) 
 
USA 
 
Lee et al., 2013 
(n=36)(27) 
 
Malaysia 
79.1 years  
 
Intervention = 256 
Control = 226 
Lost to follow up: 195 
(total study) 
 
 
65.0 years 
 
Intervention = 18 
Control = 18 
Lost to follow up = 1 
 
 
 
 
International 
Working Group on 
MCI Guidelines(83) 
 
 
 
 
 
Petersen Criteria 
(2004)(82) 
Intervention group: twice-daily doses of 120-
mg G biloba extractor.   
Control group: received an identically 
appearing placebo  
 
 
 
 
Intervention group: 3 x 1-g soft gelatine 
capsules each day, each containing 430 mg of 
DHA and 150 mg of EPA.  
Control group: isocaloric placebo corn oil (0.6 g 
linoleic acid) 
 
6.1 years 
 
 
 
 
 
 
 
12 
months 
Diagnosis of Dementia by DSM-IV 
Criteria, Modified MMSE, CDR,   
ADAS-Cog 
 
 
 
 
 
Memory: Visual reproduction I and 
II, Rey Auditory Verbal Learning Test 
(RAVLT), Digit span backward; 
Executive Function and attention: 
Clock drawing test (CDT), Digit span 
forward; Psychomotor speed: Digit 
symbol substitution test; Visuospatial 
skills: Matrix reasoning, Block 
design; Global cognitive function: 
MMSE 
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Table 2: Overview of study characteristics 
Author, Year 
and Location 
MCI sample 
characteristics  
Diagnostic 
Criteria for MCI 
Intervention Study 
Duration 
Outcome Measures 
Petersen et al., 
2005(31) 
 
(total study 
n=769) 
 
USA and Canada 
 
 
72.9 years 
 
Donepezil = 253 
Vitamin E = 257 
Placebo = 259  
Lost to follow up: 230 
(total study) 
 Petersen (1999)(84) Intervention group:  
(1) 2000 IU of vitamin E, placebo donepezil, 
and a multivitamin daily;  (2) 10 mg of 
donepezil, placebo vitamin E, and a 
multivitamin daily. The multivitamin contained 
15 IU of vitamin E. The initial dose of vitamin E 
was 1000 IU daily, and the dose was increased 
to 2000 IU (1000 IU twice daily) after six 
weeks. 
Control group: received a placebo vitamin E, 
placebo donepezil, and a multivitamin daily.  
3 years Primary end-point: time to 
development of possible of probable 
Alzheimer’s disease; Secondary: 
MMSE, ADAS-Cog, Global CDR 
CDR sum of boxes, The Global 
Deterioration Scale 
Neuropsychological Battery 
consisting of: New York University 
paragraph recall test, Symbol Digit 
Modalities test, category fluency test, 
number-cancellation test, Boston 
naming test, digits-backwards test, 
clock drawing test, Maze tracing task 
 
Desideri et al., 
2012(34) 
(n=90) 
 
Italy  
71.2 years 
 
High = 30 
Medium = 30 
Low = 30 
Lost to follow up: 3 
(included in analysis) 
 
Petersen Criteria 
(2004)(82) 
Intervention group: once daily a dairy-based 
cocoa drink containing cocoa flavanols either at 
- (1) high (HF; _990 mg of flavanols per 
serving) (2) intermediate (IF; _520 mg of 
flavanols per serving) (3) low level (LF; _45 mg 
of flavanols per serving)  
8 weeks MMSE, Trail Making Test A and B, 
Verbal Fluency Test  
 
 
 
 
Krikorian et al., 
2010a(35) 
 
(n=12) 
 
USA 
72.8 years 
Male and female 
 
Intervention = 5 
Control = 7 
 
Lost to follow up = 0 
Clinical Dementia 
Rating (CDR)(81) 
Intervention group: 100% Concord grape juice. 
A dosing schedule was instituted determined by 
body weight to maintain daily consumption 
between 6-9ml/kg, a range consistent with other 
human grape juice trials. Taken daily  in equal, 
divided dosages with the morning, midday and 
evening meals 
Control: contained no juice or natural 
polyphenol  
12 weeks Memory: California Verbal Learning 
Test (CVLT), Spatial Paired Associate 
Learning Test 
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Table 2: Overview of study characteristics 
Author, Year 
and Location 
MCI sample 
characteristics  
Diagnostic 
Criteria for MCI 
Intervention Study 
Duration 
Outcome Measures 
Krikorian et al., 
2010b(36) 
 
(n=9) 
 
USA 
76.2 years 
Male and female 
 
Intervention = No detail 
Control = No detail 
 
Lost to follow up= No 
detail 
Clinical Dementia 
Rating (CDR)(81) 
Intervention group: Wild Blueberry Juice 
prepared from ripe, frozen wild (lowbush) 
blueberries. Taken daily in equal divided 
dosages with morning, mid-day and evening 
meals. Daily consumption was maintained 
between 6- 9 mL/kg by using a dosing schedule 
determined by body weight. 
Control: contained no juice or natural 
polyphenol  
 
12 weeks Memory: Verbal Paired Associate 
Learning test (V-PAL), California 
Verbal Learning Test (CVLT) 
 
 
 
 
 
 
Krikorian et al., 
2010c(32) 
(n=26) 
 
USA 
 
Bo et al., 2017 
(n=86)(28) 
 
China 
 
 
 
 
 
 
 
 
 
 
 
 
 
71.0 years 
Intervention = 15 
Control = 11 
Lost to follow up = no 
detail 
 
71.1 years 
Intervention = 42 
Control = 44 
Lost to follow up = 22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinical Dementia 
Rating (CDR)(81) 
 
 
 
 
Petersen Criteria 
(1999)(84) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Intervention group: chromium picolinate 
(CrPic) containing 1000 mcg elemental 
chromium. 
Control group: placebo – no details 
 
 
Intervention group: 625mg DHA + 600mg EPA 
(twice daily) 
Control group: placebo capsules containing 
olive oil (twice daily) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
12 weeks 
 
 
 
 
 
6 months 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Memory: California Verbal Learning 
Test (CVLT) 
 
fMRI scanning 
 
 
Basic Cognitive Aptitude test 
(BCATs): digit copy, Chinese 
character comparison, mental 
arithmetic, Chinese character rotation, 
recall answer of mental arithmetic, 
recognition of two‐word nouns, and 
recognition of meaningless figures. 
These seven sub‐items were 
divided into five sections: perceptual 
speed (PS), mental arithmetic 
efficiency (MAE), space imagery 
efficiency (SIE), working memory 
(WM), and recognition memory (RM) 
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Table 2: Overview of study characteristics 
Author, Year 
and Location 
MCI sample 
characteristics  
Diagnostic 
Criteria for MCI 
Intervention Study 
Duration 
Outcome Measures 
Soininen et al., 
2017(33) 
(n=311) 
 
Finland  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Zhang et al., 2017 
(n=240)(30) 
 
China  
 
 
 
 
 
 
71.0 years 
Intervention = 153 
Control = 158 
Lost to follow up/ 
discontinued = 66 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
74.5 years 
Intervention = 120 
Control = 120 
Lost to follow up = 21 
 
 
 
 
 
 
Dubois et al., 
(2007)(85) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Petersen Criteria 
(2004)(82) 
 
 
 
 
 
 
 
 
Intervention group: Medical food Souvenaid, a 
125 ml once-a-day drink containing the specific 
nutrient combination Fortasyn Connect (1200mg 
DHA, 300mg EPA, 106mg Phospholipids, 
400mg Choline, 625mg UMP, 40mg Vitamin E, 
80mg Vitamin C, 60 mcg selenium, 3 mcg 
vitamin B12, 1mg vitamin B6, 400 mcg Folic 
acid) 
Control group: 125 ml once-a-day 
control drink 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Intervention group: DHA supplementation 
(2g/day)  
Control group: corn oil 
 
 
 
 
 
 
 
24 
months 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
12 
months  
 
 
 
 
 
 
 
 
Primary end points: Composite Z 
score based on Consortium to 
Establish a Registry for Alzheimer’s 
disease (CERAD) 10-word list 
learning immediate recall, CERAD 
10-word delayed recall, CERAD 10-
word recognition, category fluency, 
and letter digit substitution test 
(LDST). Memory (CERAD 10-word 
list learning immediate recall, delayed 
recall, and recognition); Executive 
function (category fluency, Wechsler 
Memory Scale revised digit span total 
score, concept shifting test condition 
C [corrected for the zero trials], and 
LDST); neuropsychological test 
battery (NTB) total (composite Z 
score based on all 16 items of the 
NTB); Secondary end points: 
Clinical Dementia Rating- Sum of 
boxes (CDR-SB); Brain volumes 
based on MRI; Progression to 
dementia by DSM-IV Criteria 
 
Chinese version of the Wechsler Adult 
Intelligence Scale Revised (WAIS-
RC). The WAIS-RC includes 11 sub-
tests: Information, Similarities, 
Vocabulary, Comprehension, 
Arithmetic, Digit Span, Block Design, 
Picture Completion, Digit Symbol-
Coding, Object Assembly, and Picture 
Arrangement 
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Table 2: Overview of study characteristics 
Author, Year 
and Location 
MCI sample 
characteristics  
Diagnostic 
Criteria for MCI 
Intervention Study 
Duration 
Outcome Measures 
Phillips et al., 
2015(29) 
(n=57) 
 
UK 
68.7 years 
Intervention = 29 
Control = 28 
Lost to follow up = 2 
Petersen Criteria 
(2004)(82) 
Intervention group: 625mg DHA + 600mg EPA 
(twice daily) 
Control group: placebo capsules containing 
olive oil (twice daily) 
 
 
 
 
4 months MMSE; Hopkins Learning Test 
Revised and neuropsychological 
measures of executive functioning, 
language, verbal reasoning, visual 
memory  
 
 RAVLT, Rey Auditory Verbal Learning Test; SD, Standard Deviation; HVLT-R, Hopkins Verbal Learning Test – Revised; tHcy, Total Homocysteine; GI, Glycaemic Index; aMCI, amnesic Mild Cognitive Impairment; SEM, 
Standard Error of the Mean; VPAL, Verbal Paired Associates Learning; CVLT, California Verbal Learning Test; CrPic, Chromium Picolinate; CDT, Clock Drawing Test; NTB, Neuropsychological Test Battery; *Statistically 
significant difference p≤0.05 within group; **Statistically significant difference p≤0.001 within group; Statistically significant difference (p≤0.05) between intervention & control groups at study completion; - No statistically 
significant difference between intervention & control at study completion; † Statistically significant difference between intervention & control at stated time-point 
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Table 3: Summary table of cognitive function results grouped as per NIA-AA (Albert et al., 2011) criteria 
NIA-AA 
Cognitive 
Domain  
Study Intervention  Cognitive Function 
Measure used 
Intervention group and Control Group Results                                                  Between 
                                                                                                                                  Group  
                                                                                                                                  Difference 
Memory  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Horie et 
al., 
2016(37) 
Nutrition 
counselling & 
calorie restriction 
vs standard care 
RAVLT (delayed recall) 
 
RAVLT (total learning) 
 
Digit span backward 
Trail making test, part B 
Intervention (mean change 0.7, 95% CI -0.9±2.3); Control (mean change 1.7, 
95% CI 0.1±3.3) 
Intervention (mean change 3.3, 95% CI -1.3±7.9); Control (mean change 2.0, 
95% CI -2.6 ±6.7) 
Intervention (0.2, 95% CI -0.8±1.2); Control (0.1, 95% CI -0.9±1.1) 
Intervention (mean change -8.6, 95% CI -71.6±54.5); Control (mean change 5.1, 
95% CI -58.3±68.6) 
- 
 
- 
 
- 
- 
Lee et al., 
2013(27) 
Fish oil 
supplementation 
with concentrated 
DHA+EPA vs 
placebo 
RAVLT (delayed recall) 
 
 
Visual reproduction I  
 
 
Visual reproduction II 
 
 
Digit symbol substitution 
 
 
Memory Cognitive Z-
score  
Intervention (baseline mean score 6.7, 95% CI 4.897–8.442 – 12 months mean 
score 8.1, 95% CI   6.645–9.462); Control (baseline mean score 6.1, 95% CI 
4.431–7.860- 12 months mean score 5.0, 95% CI 3.587–6.312) 
Intervention (baseline mean score 20.0, 95% CI 15.234–24.820 – 12 months 
mean score 29.2, 95% CI 25.207–33.269); Control (baseline mean score 21.0, 
95% CI 16.394–25.666 – 12 months mean score 23.1, 95% CI 19.154–26.952) 
Intervention (baseline mean score 13.3, 95% CI 8.297–18.362 – 12 months mean 
score 20.8, 95% CI 15.564–26.110); Control (baseline mean score 12.6, 95% CI 
7.710–17.445 – 12 months mean score 18.0, 95% CI 12.943–23.143) 
Intervention (baseline mean score 5.5, 95% CI 3.723–7.218 – 12 months mean 
score 5.5, 95% CI 3.723–7.218); Control (baseline mean score 4.9, 95% CI 
3.254–6.634 – 12 months 4.9, 95% CI 3.254–6.634) 
Intervention (mean change 0.96 (SD 0.76)**); Control (mean change 0.16, (SD 
0.59)) 
 
 
 
 
 
 
- 
 
 
- 
 
 
 
Petersen 
et al., 
2005(31) 
2000 IU vit E, 
10mg donepezil, or 
placebo 
Memory Z Score (ADAS 
recall scores & New York 
University recall scores) 
Intervention (6 months, Z score -0.10, SD ±0.48; 36 months Z score -0.31, 
SD±0.59); Control (6 months, Z score -0.17, SD ±0.47; 36 months Z score -0.28, 
SD ±0.62) 
- 
Ma et al., 
2016(24) 
oral folic acid (400 
μg/day) vs 
conventional 
treatment 
 
Digit Span Intervention (baseline mean score 9.27 (SD ±3.11) - 6 months mean score 13.05 
(SD ±3.07); Control (baseline mean score 8.87 (SD ±2.70) - 6 months mean 
score 9.75 (SD±3.14) 
 
 RAVLT, Rey Auditory Verbal Learning Test; SD, Standard Deviation; HVLT-R, Hopkins Verbal Learning Test – Revised; tHcy, Total Homocysteine; GI, Glycaemic Index; aMCI, amnesic Mild Cognitive Impairment; SEM, 
Standard Error of the Mean; VPAL, Verbal Paired Associates Learning; CVLT, California Verbal Learning Test; CrPic, Chromium Picolinate; CDT, Clock Drawing Test; NTB, Neuropsychological Test Battery; *Statistically 
significant difference p≤0.05 within group; **Statistically significant difference p≤0.001 within group; Statistically significant difference (p≤0.05) between intervention & control groups at study completion; - No statistically 
significant difference between intervention & control at study completion; † Statistically significant difference between intervention & control at stated time-point 
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Table 3: Summary table of cognitive function results grouped as per NIA-AA (Albert et al., 2011) criteria 
NIA-AA 
Cognitive 
Domain  
Study Intervention  Cognitive Function 
Measure used 
Intervention group and Control Group Results                                                  Between 
                                                                                                                                  Group  
                                                                                                                                  Difference 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
De Jager 
et al., 
2012(25) 
0.8mg folic acid, 
0.5mg vitamin B12 
and 20mg vitamin 
B6 vs placebo 
HVLT-R (subgroup 
analyses, with baseline 
tHcy levels) 
CERAD (subgroup 
analyses, with baseline 
tHcy levels) 
The odds of correctly remembering a word from the list of 12 in the HVLT test 
were 69% greater for a person in the high tHcy group if they were taking B 
vitamins than if they were taking placebo (OR =1.69) 
The average number of words was 9.4% greater at follow up in those on B 
vitamin treatment in the high tHcy group, compared with the placebo (OR=0.09) 
 
 
 
 
 
 
Bayer-
Carter et 
al., 
2011(38) 
High fat/high GI 
diet vs Low fat/ low 
GI diet 
Brief Visuospatial 
Memory Test  
 
 
 
 
Story recall 
 
 
 
 
 
Word list 
 
aMCI Low diet baseline mean score 7.39 (SEM 0.71) – week 4 mean score 8.31 
(SEM 0.62); aMCI high diet baseline mean score 8.27 (SEM 0.66) – week 4 
mean score 8.40 (SEM 0.58); Healthy controls High diet baseline mean score 
9.89 (SEM 0.85) – week 4 mean score 9.56 (SEM 0.74); Healthy controls low 
diet baseline mean score of 8.27 (SEM 0.77) – week 4 mean score 9.82 (SEM 
0.67) 
aMCI Low diet baseline mean score 18.48 (SEM 1.43) – week 4 mean score 
21.46 (SEM 1.70); aMCI High diet baseline mean score 20.37 (SEM 1.31) – 
week 4 mean score 22.30 (SEM 1.59); Healthy controls High diet baseline mean 
score 22.69 (SEM 1.7 4)- week 4 mean score 23. 19 (SEM 2.04); Healthy 
controls Low diet baseline mean score 21.09 (SEM 1.55) – week 4 mean score 
19.90 (SEM 1.95) 
aMCI Low diet baseline mean score 11.62 (SEM 0.76) – week 4 mean score 
11.77 (SEM 0.80), aMCI High diet baseline mean score 11.33 (SEM 0.71); 
Healthy controls Low diet baseline mean score 13.27 (SEM 0.93) – week 4 mean 
score 13.27 (SEM 0.96), healthy controls High diet baseline mean score 12.79 
(SEM 0.92) – week 4 mean score 13.67 (SEM 0.95) 
 
- 
 
 
 
 
 
- 
 
 
 
 
 
- 
Krikorian 
et al., 
2012(12) 
High carbohydrate 
vs a very low 
carbohydrate 
Trail making test, part B 
 
 
V-PAL 
Intervention (pre-intervention mean score 79.2 seconds vs post intervention 
mean score 82.9 seconds, F(1, 20) = 0.46, p = 0.50)  
Control (no detail) 
Intervention (pre-intervention mean score 11.8 seconds vs post intervention 
mean score 14.6 seconds, F(1, 20) = 6.45, p = 0.01);  
Control (no detail) 
- 
 
 
- 
 RAVLT, Rey Auditory Verbal Learning Test; SD, Standard Deviation; HVLT-R, Hopkins Verbal Learning Test – Revised; tHcy, Total Homocysteine; GI, Glycaemic Index; aMCI, amnesic Mild Cognitive Impairment; SEM, 
Standard Error of the Mean; VPAL, Verbal Paired Associates Learning; CVLT, California Verbal Learning Test; CrPic, Chromium Picolinate; CDT, Clock Drawing Test; NTB, Neuropsychological Test Battery; *Statistically 
significant difference p≤0.05 within group; **Statistically significant difference p≤0.001 within group; Statistically significant difference (p≤0.05) between intervention & control groups at study completion; - No statistically 
significant difference between intervention & control at study completion; † Statistically significant difference between intervention & control at stated time-point 
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Table 3: Summary table of cognitive function results grouped as per NIA-AA (Albert et al., 2011) criteria 
NIA-AA 
Cognitive 
Domain  
Study Intervention  Cognitive Function 
Measure used 
Intervention group and Control Group Results                                                  Between 
                                                                                                                                  Group  
                                                                                                                                  Difference 
 
 
 
 
 
 
 
Krikorian 
et al., 
2010a(35) 
Concord grape 
juice 
supplementation vs 
placebo  
CVLT learning 
 
CVLT recall 
 
Spatial Paired Associate 
Learning Task 
Intervention mean change 3.4; Control mean change 0.0; ANCOVA analysis 
intervention vs control F(1,8) = 5.55, p = 0.04, Cohen’s f = 0.28 
Intervention mean change 1.2; Control mean change -0.4; ANCOVA analysis 
intervention vs control p = 0ꞏ10; Cohen’s f = 0ꞏ35 
Intervention mean change 1.7; Control mean change -0.4; ANCOVA analysis 
intervention vs control p = 0ꞏ12; Cohen’s f = 0ꞏ67 
 
 
- 
 
- 
Krikorian 
et al., 
2010b(36) 
Wild Blueberry 
juice 
supplementation vs 
placebo 
V-PAL 
 
CVLT 
Intervention (baseline mean score 9.3 vs week 12 mean score 13.2*); Control (no 
detail); ANCOVA analysis intervention vs control F(1,13) = 5.58 
Intervention (baseline mean score 7.2 vs week 12 mean score 9.6*); Control (no 
detail); ANCOVA analysis intervention vs control F(1,13), = 2.27 
 
 
- 
Krikorian 
et al., 
2010c(32) 
 
 
 
 
 
 
 
 
 
Desideri 
et al., 
2012(34) 
Bo et al., 
2017(28) 
 
Chromium 
picolinate (CrPic) 
supplementation  vs 
placebo 
 
 
 
 
 
 
 
 
990 mg HF vs IF vs 
LF cocoa flavanols 
per day 
480mg of DHA + 
720mg of EPA 
daily vs placebo 
 
CVLT Learning 
 
 
CVLT Delay Recall 
 
 
CVLT Long Delay Recall 
 
 
CVLT Recognition 
Memory 
 
Verbal Fluency  
 
 
Working memory  
 
Recognition memory 
 
Intervention vs Control mean score at 12 weeks (46.8 vs 45.8) 
Intrusion errors intervention vs control at 12 weeks (0.20 vs 1.27); F (1, 23) = 
6.48; Cohen’s f = 0.51) 
Intervention vs Control mean score at 12 weeks (9.4 vs 8.4)          
Intrusion errors intervention vs control at 12 weeks (0.98 vs 2.3), F (1, 23) = 
3.35, Cohen’s f = 0.35) 
Intervention vs Control mean score at 12 weeks (9.3 vs 9.5) 
Intrusion errors intervention vs control at 12 weeks (0.98 vs 2.3), F (1, 23) = 
3.35, Cohen’s f = 0.35) 
Intervention vs Control mean score at 12 weeks (14.4 vs 14.2)  
Intrusion errors intervention vs control at 12 weeks (0.88 vs 2.2), F (1, 23) = 
2.94, Cohen’s f = 0.34) 
HF (mean change +8.0 (SD+-5.3) words per 60 seconds**); IF (mean change 
+5.1 (SD+-3.1) words per 60 seconds**), LF (mean change +1.2 (SD+-2.7) 
words per 60 seconds*)  
Intervention mean difference 3.32 (SD ±3.45); Control mean difference 1.38 (SD 
±2.66) 
Intervention: mean change 1.55 (SD ±3.96); Control mean change 1.98 (SD 
±3.13) 
- 
 
 
- 
- 
 
- 
- 
 
- 
- 
 
 
 
 
 
 
- 
 RAVLT, Rey Auditory Verbal Learning Test; SD, Standard Deviation; HVLT-R, Hopkins Verbal Learning Test – Revised; tHcy, Total Homocysteine; GI, Glycaemic Index; aMCI, amnesic Mild Cognitive Impairment; SEM, 
Standard Error of the Mean; VPAL, Verbal Paired Associates Learning; CVLT, California Verbal Learning Test; CrPic, Chromium Picolinate; CDT, Clock Drawing Test; NTB, Neuropsychological Test Battery; *Statistically 
significant difference p≤0.05 within group; **Statistically significant difference p≤0.001 within group; Statistically significant difference (p≤0.05) between intervention & control groups at study completion; - No statistically 
significant difference between intervention & control at study completion; † Statistically significant difference between intervention & control at stated time-point 
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Table 3: Summary table of cognitive function results grouped as per NIA-AA (Albert et al., 2011) criteria 
NIA-AA 
Cognitive 
Domain  
Study Intervention  Cognitive Function 
Measure used 
Intervention group and Control Group Results                                                  Between 
                                                                                                                                  Group  
                                                                                                                                  Difference 
Soininen 
et al., 
2017(33) 
Zhang et 
al., 
2017(30) 
Phillips et 
al., 
2015(29) 
Souvenaid, a 125ml 
once-a-day drink vs 
control  
2g/day DHA vs 
placebo 
 
625mg EPA 
+600mg DHA vs 
placebo 
NTB Memory Z score 
 
 
Information Test 
Digit Span  
 
Immediate Verbal 
Memory  
Delayed Verbal Memory 
 
Recognition Verbal 
Memory  
Visual Memory 
Intervention mean change at 24 months, 0.003 (SD 0.569); Control mean change 
at 24 months -0.130 (SD 0.619) 
 
Intervention mean score 12.28 (SD ±3.56); Control mean score 10.82 (SD±2.62)  
Intervention mean score 13.44 (SD±3.66); Control mean score 10.25 (SD±3.42) 
 
Intervention mean score (month 1, 19.42 (SD 3.49) -month 4, 17.46 (SD 4.52)); 
Control mean score (month 1, 20.50 (SD 4.31) - month 4, 19.38 (SD 4.65))  
Intervention mean score (month 1, 4.85 (SD 2.91) -month 4, 4.34 (SD 2.74)); 
Control mean score (month 1, 5.23 (SD 2.63) -month 4, 4.65 (SD 2.79)) 
Intervention mean score (month 1, 8.92 (SD 2.06) -month 4, 8.38 (SD 2.30)); 
Control mean score (month 1, 9.00 (SD 2.80) -month 4, 8.00 (SD 2.55)) 
Intervention mean score (month 1, 11.58 (SD 2.19) -month 4, 12.77 (SD 2.67); 
Control mean score (month 1, 11.50 (SD 2.60) -month 4, 11.85 (SD 1.95)) 
- 
 
 
 
 
 
- 
 
- 
 
- 
 
- 
Executive 
Function 
Lee et al., 
2013(27) 
Fish oil 
supplementation 
with concentrated 
DHA+EPA vs 
placebo 
Digit Symbol Substitution  
 
 
Clock Drawing Test 
(CDT) 
 
Executive Function Z 
Score (cumulative score 
of all tests used) 
Intervention (baseline mean score 5.5, 95% CI 3.723–7.218 – 12 months mean 
score 5.5, 95% CI 3.723–7.218); Control (baseline mean score 4.9, 95% CI 
3.254–6.634 – 12 months mean score 4.9, 95% CI 3.254–6.634) 
Intervention (baseline mean score 7.3, 95% CI 6.810–7.880 – 12 months mean 
score 7.8, 95% CI 7.142–8.477); Control (baseline mean score 7.5, 95% CI 
6.935–7.969 – 12 months mean score 7.8, 95% CI 7.145–8.436) 
Intervention (mean change 0.52 (SD 0.869)*); Control (mean change −0.238 
(0.683)) 
- 
 
 
- 
 
 
- 
Petersen 
et al., 
2005(31) 
2000 IU vit E, 10 
mg donepezil or 
placebo 
Executive Function Z 
score (Digits backwards 
test, Symbol digit 
modalities test & Number 
- cancellation test) 
Intervention (6 months Z score 0.11, SD±0.41† – 36 months Z score  -0.19, 
SD±0.48); Control (6 months Z score 0.04, SD±0.42 – 36 months Z score -0.19 
SD±0.53) 
- 
 RAVLT, Rey Auditory Verbal Learning Test; SD, Standard Deviation; HVLT-R, Hopkins Verbal Learning Test – Revised; tHcy, Total Homocysteine; GI, Glycaemic Index; aMCI, amnesic Mild Cognitive Impairment; SEM, 
Standard Error of the Mean; VPAL, Verbal Paired Associates Learning; CVLT, California Verbal Learning Test; CrPic, Chromium Picolinate; CDT, Clock Drawing Test; NTB, Neuropsychological Test Battery; *Statistically 
significant difference p≤0.05 within group; **Statistically significant difference p≤0.001 within group; Statistically significant difference (p≤0.05) between intervention & control groups at study completion; - No statistically 
significant difference between intervention & control at study completion; † Statistically significant difference between intervention & control at stated time-point 
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Table 3: Summary table of cognitive function results grouped as per NIA-AA (Albert et al., 2011) criteria 
NIA-AA 
Cognitive 
Domain  
Study Intervention  Cognitive Function 
Measure used 
Intervention group and Control Group Results                                                  Between 
                                                                                                                                  Group  
                                                                                                                                  Difference 
Horie et 
al., 
2016(37) 
Nutrition 
counselling & 
calorie restriction 
vs standard care 
Trail making test, part B 
 
Phonemic fluency 
 
Semantic Fluency 
 
Modified Wisconsin Card 
Sorting Test 
Intervention (mean change -8.6, 95% CI -71.6±54.5); Control (mean change 5.1, 
95% CI -58.3±68.6) 
Intervention (mean change 0.1, 95% CI -0.5±5.1); Control (mean change 2.0, 
95% CI -3.1±7.1) 
Intervention (mean change 1.1, 95% CI -1.4±3.6); Control (mean change 1.9, 
95% CI -0.6±4.4) 
Intervention (mean change 0.4, 95% CI -0.3±1.0); Control (mean change 0.7, 
95% CI -0.1±1.4) 
- 
 
- 
 
- 
 
- 
Krikorian 
et al., 
2012(12) 
High carbohydrate 
diet vs very low 
carbohydrate 
Trail making test, part B Intervention (pre-intervention mean score 79.2 seconds vs post intervention 
mean score 82.9 seconds, F(1, 20) = 0.46); Control (no detail) 
- 
Bayer-
Carter et 
al., 2011 
(38) 
High fat/high GI 
diet vs Low fat/ low 
GI diet 
Trail making test, part B 
Stroop colour word test 
Verbal fluency 
The authors did not include these data in their published paper, merely stating 
no diet related changes in the text 
- 
De Jager 
et al., 
2012(25) 
 
Desideri 
et al., 
2012(34) 
Soininen 
et al., 
2017(33) 
Phillips et 
al., 
2015(29) 
0.8mg folic acid, 
0.5mg vitamin B12 
and 20mg vitamin 
B6 vs placebo 
990 mg HF vs IF vs 
LF cocoa flavanols 
per day 
Souvenaid, a 125ml 
once-a-day drink vs 
control  
625mg EPA 
+600mg DHA vs 
placebo 
CLOX (subgroup 
analyses, with baseline 
tHcy levels) 
 
Trail making test, part B 
 
 
NTB Executive Function 
Z score 
 
CLOX2 
The odds of a correctly drawn item from CLOX1, after controlling for 
confounders (CLOX2 at follow-up, CLOX1 at baseline, age, education, APOE 
Ɛ4 status and sex), was 30% greater in those receiving B-vitamins in comparison 
to placebo (OR= 0.26) 
HF (mean change -29.2 (SD ±8.0) seconds**), IF (mean change -22.8 (SD±5.1) 
seconds**) LF (mean change +3.8 (SD±16.3) seconds) 
 
Intervention mean change at 24 months -0.145 (SD 0.445); Control mean change 
at 24 months -0.039 (SD 0.506) 
 
Intervention mean score (month 1, 14.08 (SD 0.89)-month 4, 14.08 (SD 14.08)); 
Control mean score (month 1, 14.38 (SD 0.75)-month 4, 14.27 (SD 0.67)) 
 
 
 
 
 
 
 
- 
 
 
- 
 RAVLT, Rey Auditory Verbal Learning Test; SD, Standard Deviation; HVLT-R, Hopkins Verbal Learning Test – Revised; tHcy, Total Homocysteine; GI, Glycaemic Index; aMCI, amnesic Mild Cognitive Impairment; SEM, 
Standard Error of the Mean; VPAL, Verbal Paired Associates Learning; CVLT, California Verbal Learning Test; CrPic, Chromium Picolinate; CDT, Clock Drawing Test; NTB, Neuropsychological Test Battery; *Statistically 
significant difference p≤0.05 within group; **Statistically significant difference p≤0.001 within group; Statistically significant difference (p≤0.05) between intervention & control groups at study completion; - No statistically 
significant difference between intervention & control at study completion; † Statistically significant difference between intervention & control at stated time-point 
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Table 3: Summary table of cognitive function results grouped as per NIA-AA (Albert et al., 2011) criteria 
NIA-AA 
Cognitive 
Domain  
Study Intervention  Cognitive Function 
Measure used 
Intervention group and Control Group Results                                                  Between 
                                                                                                                                  Group  
                                                                                                                                  Difference 
Attention 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Horie et 
al., 
2016(37) 
 
 
 
Nutrition 
counselling & 
calorie restriction 
vs standard care 
Digit span forward 
 
Digit span backward 
 
Trail making test, part A  
Intervention (mean change -0.4, 95% CI -1.1±0.3); Control (mean change 0.1, 
95% CI -0.6±0.9)  
Intervention (mean change 0.2, 95% CI -0.8±1.2); Control (mean change 0.1, 
95% CI -0.9±1.1) 
Intervention (mean change -6.1 95% CI -22.6±10.4); Control (mean change -0.7, 
95% CI -17.3±15.9) 
- 
 
- 
 
- 
Lee et al., 
2013(27) 
 
 
 
 
 
 
 
Desideri 
et al., 
2012(34) 
Zhang et 
al., 
2017(30) 
Philips et 
al., 
2015(29)  
Fish oil 
supplementation 
with concentrated 
DHA+EPA vs 
placebo  
 
 
 
 
990 mg HF vs IF vs 
LF cocoa flavanols 
per day 
2g/day DHA vs 
placebo  
 
625mg EPA 
+600mg DHA vs 
placebo 
 
 
 
 
 
CDT  
 
 
Digit span forward test 
 
 
Attention Z Score  
 
 
Trail making test, part A 
 
 
Digit span  
 
 
Basic Attention 
Intervention (baseline mean score 7.3, 95% CI 6.810–7.880 – 12 months mean 
score 7.8, 95% CI 7.142–8.477); Control (baseline mean score 7.5, 95% CI 
6.935–7.969 – 12 months mean score 7.8, 95% CI 7.145–8.436) 
Intervention (baseline mean score 8.0, 95% CI 6.99 –9.04 – 12 months mean 
score 9.6, 95% CI 8.437–10.749); Control (baseline mean score 8.5, 95% CI 
7.554–9.529 – 12 months mean score 8.0, 95% CI 6.877–9.113) 
Intervention (mean change 0.52 (SD 0.869)*); Control (mean change −0.238 
(0.683)) 
 
HF (mean change -14.3 (SD±4.2) seconds**), IF (mean change -8.8 (SD±3.4) 
seconds**), LF (mean change +1.1 (SD±13.0) seconds) 
 
Intervention mean score 13.44 (SD±3.66); Control mean score 10.25 (SD±3.42) 
 
 
Intervention mean score (month 1, 6.38 (SD 1.47) - month 4, 6.54 (SD 1.33); 
Control mean score (month 1, 6.65 (1.36) - month 4, 6.77 (SD 1.31)) 
- 
 
 
 
 
 
- 
 
 
 
 
 
 
 
 
- 
 RAVLT, Rey Auditory Verbal Learning Test; SD, Standard Deviation; HVLT-R, Hopkins Verbal Learning Test – Revised; tHcy, Total Homocysteine; GI, Glycaemic Index; aMCI, amnesic Mild Cognitive Impairment; SEM, 
Standard Error of the Mean; VPAL, Verbal Paired Associates Learning; CVLT, California Verbal Learning Test; CrPic, Chromium Picolinate; CDT, Clock Drawing Test; NTB, Neuropsychological Test Battery; *Statistically 
significant difference p≤0.05 within group; **Statistically significant difference p≤0.001 within group; Statistically significant difference (p≤0.05) between intervention & control groups at study completion; - No statistically 
significant difference between intervention & control at study completion; † Statistically significant difference between intervention & control at stated time-point 
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Table 3: Summary table of cognitive function results grouped as per NIA-AA (Albert et al., 2011) criteria 
NIA-AA 
Cognitive 
Domain  
Study Intervention  Cognitive Function 
Measure used 
Intervention group and Control Group Results                                                  Between 
                                                                                                                                  Group  
                                                                                                                                  Difference 
Language  Horie et 
al., 
2016(37) 
Nutrition 
counselling & 
calorie restriction 
vs standard care 
Semantic fluency 
 
Phonemic fluency 
Intervention (mean change 1.1, 95% CI -1.4±3.6); Control (mean change 1.9, 
95% CI -0.6±4.4) 
Intervention (mean change 0.1, 95% CI -0.5±5.1); Control (mean change 2.0, 
95% CI -3.1±7.1) 
- 
 
- 
Petersen 
et al., 
2005(31) 
2000 IU vit E, 10 
mg donepezil, or 
placebo 
Language Z Score 
(Boston naming test & 
Category fluency test) 
Intervention (6 months Z score 0.07, SD±0.23† – 36 months Z score  -0.10, 
SD±0.35); Control (6 months Z score 0.03, SD±0.23 – 36 months -0.08, 
SD±0.33) 
 
- 
Visuo-
spatial 
Skills 
(VS) 
Lee et al., 
2013(27) 
Fish oil 
supplementation 
with concentrated 
DHA+EPA vs 
placebo 
Matrix reasoning block 
design test 
 
VS Z score  
Intervention (baseline mean score 7.6, 95% CI 6.37–8.75 – 12 months mean 
score 7.1, 95% CI 6.27–7.96); Control (baseline mean score 7.3, 95% CI 6.16–
8.45 – 12 months mean score 7.9, 95% CI 7.07–8.71) 
Intervention (mean change 0.17 (SD 0.84)); Control (mean change 0.04 (SD 
0.60)) 
 
- 
 
- 
Petersen 
et al., 
2005(31) 
2000 IU vit E, 10 
mg donepezil, or 
placebo 
VS Z score (CDT) Intervention (6 month Z score 0.03, SD± 0.34 – 36 months Z score -0.12, 
SD±0.37); Control (6 month Z score -0.01, SD±0.34 – 36 months Z score -0.11, 
SD±0.39) 
 
- 
Ma et al., 
2016(24) 
 
Zhang et 
al., 
2017(30) 
folic acid 
(400μg/day) vs 
control 
2mg DHA vs 
placebo  
Block design test 
 
 
Block design test  
Intervention (baseline mean score 9.77 (SD±5.41) – 6 months mean score 13.28 
(SD±4.21)); Control (baseline mean score 9.93 (SD±2.273)- 6 months mean 
score 11.33 (SD±3.11)) 
Intervention (baseline mean score 10.25 (SD±5.30 – 12 months mean score 
11.19 (SD±4.07); Control (baseline mean score 9.63 (SD±2.46 – 12 months 
mean score 10.43 (SD±3.51))  
 
 
 
 
 
- 
 
